Schedule 13D ownership disclosure
Iovance Biotherapeutics Inc
Security class unavailable · CUSIP: 462260100
Event date: 2022-12-02
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 20,000,000
- Percent of class
- 12.5200%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-23-003844
- Form type
- SC 13D
- Filer
- IOVANCE BIOTHERAPEUTICS, INC.
- CIK
- CIK 1425205
- Filed
- Jan 13, 2023
- Reporting period
- Dec 02, 2022
- Description
- Schedule 13D beneficial ownership